Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Activision Blizzard

Citrix Systems

Discovery

Discovery Communications

Fidelity National Information

FleetCor Technologies

Global Payments

IPG Photonics

Leidos Hld

Las Vegas Sands

Lamb Weston Hlds

MarketAxess Holdings

Penn Entertainment

PayPal

Twitter

V.F.

ViacomCBS

Viatris

Wynn Resorts

Zimmer Biomet Hlds

Retail tax loss selling and institutional portfolio window dressing can artificially depress underperforming stocks in the final trading days of the calendar year. Buying a basket of underperformers, the goal is to outperform the S&P 500 by five percentage points at some point during January 2022.

A 2021 Year-End Portfolio Of Bounce Candidates Expected To Outperform In January

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

Will expand patient access to breakthrough BPH treatment Will expand patient access to breakthrough BPH treatment

Teleflex Receives Reimbursement Approval for the UroLift® System in Japan

The stock price of Teleflex, best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a decline of 12% over the last month, while it was down over 4% last week. The company recently announced a recall of its of Arrow-Trerotola Over-The-Wire.

What's Next For Teleflex Stock After Its Recent PTD Recall?

Teleflex Incorporated (NYSE: TFX) announced a worldwide recall of Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR.  The FDA classified the recall as a Class I recall, wherein using or exposure to a defective product will cause serious adverse health consequences or death.

Teleflex Recalls Percutaneous Thrombolytic Device Kits

WAYNE, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of Arrow-Trerotola™ Over-The-Wire PTD® Kit Percutaneous Thrombolytic Device: 7FR. The Arrow-Trerotola Percutaneous Thrombolytic Device (PTD) Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous (AV) fistulae and synthetic dialysis grafts.

Teleflex Incorporated Announces Worldwide Recall of Arrow-Trerotola™ Over-The-Wire PTD® Kit Percutaneous Thrombolytic Device: 7FR

WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it was named a winner in the MedReps.com Best Places to Work in Medical Sales 2022 survey, earning the Number 1 spot for large companies and making this the fifth consecutive year the company has been on the list.

Teleflex Earns Top Spot in MedReps Best Places to Work 2022 Ranking

WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and CFO, Teleflex Incorporated (NYSE: TFX), is pleased to participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. From November 22nd to December 2nd, 2021, registered attendees can access a pre-recorded presentation via the Piper Sandler conference site. Teleflex will be participating in 1x1 meetings on December 2, 2021. Investor meetings can be requested exclusively via Piper Sandler.

Teleflex to Participate in the 33rd Annual Virtual Piper Sandler Healthcare Conference

Innovative, cloud-based digital platform supports Urologists' access to enhanced training with the UroLift® System through remote collaboration tools Innovative, cloud-based digital platform supports Urologists' access to enhanced training with the UroLift® System through remote collaboration tools

Teleflex Integrates Medical Education and Training with Explorer Surgical to Expand Urologists' Access to Procedural Expertise

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. The Final Rule was released on November 3, 2021 and updates to payment policies, payment rates and other provisions for services furnished under the MPFS are effective January 1, 2022.

Teleflex Comments on the Centers for Medicare & Medicaid Services 2022 Medicare Physician Fee Schedule Final Rule

Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.

Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up

WAYNE, Pa., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that the UroLift® System was honored by DTC Perspectives with a Bronze Award in the “Best New Branded Television Campaign” category and an Honorable Mention in the “Best Branded Website” category. The National Advertising Awards were announced at the Annual DTC National Conference in Boston, which was held October 12-14.

The UroLift® System Receives Bronze Award for Best New Branded Television Campaign and Honorable Mention in the Best Branded Website Category from DTC Perspectives

Teleflex's (TFX) CEO Liam Kelly on Q3 2021 Results - Earnings Call Transcript

Teleflex (TFX) delivered earnings and revenue surprises of 15.84% and 0.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Q3 Earnings and Revenues Surpass Estimates

WAYNE, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 26, 2021.

Teleflex Reports Third Quarter 2021 Results and Full Year Outlook

Teleflex (NYSE:TFX) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.

Teleflex's Earnings: A Preview

Study Evaluates Effectiveness of QuikClot Control+® Hemostatic Device in Patients Undergoing Cardiac Surgery Study Evaluates Effectiveness of QuikClot Control+® Hemostatic Device in Patients Undergoing Cardiac Surgery

Teleflex Completes Enrollment in Cardiac IDE Study

Pool

Roper Technologies

STERIS

Visa

Villere & Co. was established in 1911 and has been operated by the Villere family for over a decade. The team invests selectively and independently—taking a long-term perspective.

The Top 5 Holdings of Villere & Co.

WAYNE, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 28, 2021.

Teleflex Announces Third Quarter 2021 Earnings Conference Call Information

Late-Breaking Data Presentation Reveals How UroLift PUL's Post-Operative Events Compare With Other Minimally Invasive Procedures and Traditional Surgery for the Treatment of BPH Late-Breaking Data Presentation Reveals How UroLift PUL's Post-Operative Events Compare With Other Minimally Invasive Procedures and Traditional Surgery for the Treatment of BPH

Teleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures at the American Urological Association 2021 Annual Meeting

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

New real-world data findings along with new product evolutions demonstrate why the UroLift ® System is the right solution for most BPH patients

Teleflex Unveils the UroLift Advanced Tissue Control (ATC)® System and the UroLift® 2 System and Real-World Data Presentations at the American Urological Association 2021 Annual Meeting

WAYNE, Pa., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021 at 8:00 a.m. (ET).

Teleflex to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

WAYNE, Pa., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of clinical data for the UroLift ® System in the peer-reviewed journal Prostate Cancer and Prostatic Disease . This study explains the mechanism of action through which the UroLift System provides long-term durability and sustained results for patients with benign prostatic hyperplasia (BPH), also referred to as enlarged prostate.

New Study Provides Insights into the Biocompatibility and Durability of the UroLift® System in Improving Benign Prostatic Hyperplasia Symptoms

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo 2021 Virtual Healthcare Conference on Thursday, September 9, 2021 at 12:40 p.m. (ET).

News for Teleflex Stock (TFX)